Repositorio Digital de la UPF
Publication
Artículo científico (JournalArticle)
Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics
Pleural Mesothelioma (PM) is an aggressive neoplasm of the lung pleura with poor survival rates, highlighting the urgent need for novel therapeutic options. The CDK4/6 inhibitors abemaciclib and palbociclib have demonstrated promising results in patient-derived xenograft models of PM. In this study, we observed that palbociclib reduced proliferation, leading to increased cell size, enhanced SA-β-galactosidase activity, and elevated secretion of IL-6 and IL-8 (SASP), all of which are hallmarks of senescence. However, upon drug removal, the cells regrew. To enhance therapeutic efficacy, we attempted to induce cell death in palbociclib-pretreated PM cells with conventional senolytics, such as BH3 mimetics. While some cells showed sensitivity to Bcl-xL inhibitors, neither navitoclax nor the specific Bcl-xL inhibitor A-1331852, nor other BH3 mimetics targeting Bcl-2 (venetoclax) or Mcl-1 (S63845) increased cell death when combined with palbociclib. We explored the activity of signalling pathways after treatment with palbociclib and identified higher Src and STAT3 phosphorylation, as well as activation of the mTORC1 axis. Therefore, we employed inhibitors of these pathways, such as dasatinib, momelotinib or Torin-1, which did not synergise with palbociclib to kill the cells. In contrast, we found that the chemotherapeutic drug cisplatin induces permanent cell cycle arrest and complete senescence in PM cells. While both drugs increased the phosphorylation of γH2AX, the effects of cisplatin were stronger and more consistent across cell lines. The differential effects of palbociclib and cisplatin on permanent growth arrest were verified by sorting PM cells based on size and β-galactosidase activity. Our findings underscore the importance of understanding the nature of therapy-induced senescence when assessing the effectiveness of senolytics in different tumour models., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This study has been funded by Ministerio de Ciencia e Innovación y Universidades (MICINN/MCIU), which is part of Agencia Estatal de Investigación (AEI), through the Generación de Conocimiento grant numbers PID2022-140457OB-I00, PID2019-107213GB-I00/https://doi.org/10.13039/501100011033 and BFU2016-78154-R (cofunded by the European Regional Development Fund, 'A way to build Europe'), Funding by Instituto de Salud Carlos III: grants PI18/00920, PI21/00789 and PI24/00702 to EN (co-funded by the European Regional Development Fund/FEDER). Funding by AGAUR (Co-funded by European Social Fund. ESF investing in your future) 2021 FI_B 00484 to IS and 2021FI_B 00485 to MC-R Funding by Programa de Formación del Profesorado Universitario (FPU) grant agreement FPU21/06884, from the Spanish Ministry of Universities to SP-M The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.